- Home
- Publications
- Publication Search
- Publication Details
Title
Poly(ADP-ribose) polymerase inhibition: past, present and future
Authors
Keywords
-
Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 19, Issue 10, Pages 711-736
Publisher
Springer Science and Business Media LLC
Online
2020-09-03
DOI
10.1038/s41573-020-0076-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation
- (2020) Ahrum Min et al. Cancers
- Role of Akt Activation in PARP Inhibitor Resistance in Cancer
- (2020) Ferenc Gallyas Jr et al. Cancers
- Repositioning PARP inhibitors for SARS‐CoV‐2 infection (COVID‐19); a new multi‐pronged therapy for ARDS?
- (2020) Nicola Curtin et al. BRITISH JOURNAL OF PHARMACOLOGY
- ‘PARP’ing fibrosis: repurposing poly (ADP ribose) polymerase (PARP) inhibitors
- (2020) Pooja Dhileepkumar Rao et al. DRUG DISCOVERY TODAY
- Structural basis for allosteric PARP-1 retention on DNA breaks
- (2020) Levani Zandarashvili et al. SCIENCE
- Poly(ADP-ribose) Polymerase Inhibition in Acute Lung Injury: A Re-emerging Concept
- (2020) Csaba Szabo et al. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
- Pharmacologic Characterization of Fluzoparib, a Novel Poly(ADP-ribose) polymerase (PARP) Inhibitor Undergoing Clinical Trials
- (2019) Lei Wang et al. CANCER SCIENCE
- Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update
- (2019) Priyancy G. Jain et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Exploring and comparing adverse events between PARP inhibitors
- (2019) Christopher J LaFargue et al. LANCET ONCOLOGY
- Regulating Immunity via ADP-Ribosylation: Therapeutic Implications and Beyond
- (2019) Friedrich A. Kunze et al. TRENDS IN IMMUNOLOGY
- Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs
- (2019) Marianna A. Zolotovskaia et al. Frontiers in Pharmacology
- PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity
- (2019) Shiv K. Gupta et al. Frontiers in Oncology
- Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types
- (2019) Lucy Gentles et al. Cancers
- PARP Inhibitors and Parkinson’s Disease
- (2019) Abby L. Olsen et al. NEW ENGLAND JOURNAL OF MEDICINE
- PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
- (2019) Patrick G. Pilié et al. CLINICAL CANCER RESEARCH
- Enabling drug discovery for the PARP protein family through the detection of mono-ADP-ribosylation
- (2019) Alvin Z. Lu et al. BIOCHEMICAL PHARMACOLOGY
- PARP3 comes to light as a prime target in cancer therapy
- (2019) José Manuel Rodriguez-Vargas et al. CELL CYCLE
- 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer
- (2019) Rachel M. Hurley et al. GYNECOLOGIC ONCOLOGY
- Pooled analysis of phase I dose-escalation and dose cohort expansion studies of IMP4297, a novel PARP inhibitor, in Chinese and Australian patients with advanced solid tumors.
- (2019) Junning Cao et al. JOURNAL OF CLINICAL ONCOLOGY
- Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
- (2019) Kathleen N Moore et al. LANCET ONCOLOGY
- Detecting the mutational signature of homologous recombination deficiency in clinical samples
- (2019) Doga C. Gulhan et al. NATURE GENETICS
- Olaparib induces browning of in vitro cultures of human primary white adipocytes
- (2019) Lilla Nagy et al. BIOCHEMICAL PHARMACOLOGY
- PARP-1 and its associated nucleases in DNA damage response
- (2019) Yijie Wang et al. DNA REPAIR
- Tumour lineage shapes BRCA-mediated phenotypes
- (2019) Philip Jonsson et al. NATURE
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- The PARP inhibitor olaparib exerts beneficial effects in mice subjected to cecal ligature and puncture and in cells subjected to oxidative stress without impairing DNA integrity: A potential opportunity for repurposing a clinically used oncological drug for the experimental therapy of sepsis
- (2019) Akbar Ahmad et al. PHARMACOLOGICAL RESEARCH
- Effects of The Poly(ADP-ribose) Polymerase Inhibitor Olaparib in Cerulein-Induced Pancreatitis
- (2019) Akbar Ahmad et al. SHOCK
- Poly(ADP-ribose) polymerase-1 antagonizes DNA resection at double-strand breaks
- (2019) Marie-Christine Caron et al. Nature Communications
- Poly(ADP-Ribose) Links the DNA Damage Response and Biomineralization
- (2019) Karin H. Müller et al. Cell Reports
- Drug repurposing studies of PARP inhibitors as a new therapy for inherited retinal degeneration
- (2019) Ayse Sahaboglu et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial
- (2019) Michael Friedlander et al. LANCET ONCOLOGY
- Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
- (2019) Jacob J. Adashek et al. Cells
- Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials
- (2019) Jing Luo et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy
- (2019) Nicola J. Curtin et al. Nature Reviews Clinical Oncology
- PARP Inhibition in Cancer: An Update on Clinical Development
- (2019) Esha Sachdev et al. Targeted Oncology
- Oxidative Stress Increases Endogenous Complement-Dependent Inflammatory and Angiogenic Responses in Retinal Pigment Epithelial Cells Independently of Exogenous Complement Sources
- (2019) Trakkides et al. Antioxidants
- Design, Synthesis and Molecular Modeling Study of Conjugates of ADP and Morpholino Nucleosides as A Novel Class of Inhibitors of PARP-1, PARP-2 and PARP-3
- (2019) Yuliya V. Sherstyuk et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Sex differences in the effects of PARP inhibition on microglial phenotypes following neonatal stroke
- (2018) Christiane Charriaut-Marlangue et al. BRAIN BEHAVIOR AND IMMUNITY
- Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality
- (2018) Ewa Gogola et al. CANCER CELL
- Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders
- (2018) Robert J. Henning et al. Cardiovascular Toxicology
- Regulatory T cells increase after treatment with poly (ADP-ribose) polymerase-1 inhibitor in ischemic stroke patients
- (2018) Min-Young Noh et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- PARP Inhibition Prevents Ethanol-Induced Neuroinflammatory Signaling and Neurodegeneration in Rat Adult-Age Brain Slice Cultures
- (2018) Nuzhath Tajuddin et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- The Importance of Poly(ADP-Ribose) Polymerase as a Sensor of Unligated Okazaki Fragments during DNA Replication
- (2018) Hana Hanzlikova et al. MOLECULAR CELL
- Early Treatment with Poly(ADP-Ribose) Polymerase-1 Inhibitor (JPI-289) Reduces Infarct Volume and Improves Long-Term Behavior in an Animal Model of Ischemic Stroke
- (2018) Youngchul Kim et al. MOLECULAR NEUROBIOLOGY
- Insights into the biogenesis, function, and regulation of ADP-ribosylation
- (2018) Michael S Cohen et al. Nature Chemical Biology
- Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy
- (2018) Yanxin Lu et al. PHARMACOLOGY & THERAPEUTICS
- Synthesis and Evaluation of a Mitochondria-Targeting Poly(ADP-ribose) Polymerase-1 Inhibitor
- (2018) Tanja Krainz et al. ACS Chemical Biology
- PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines
- (2018) Bahram Sharif-Askari et al. BREAST CANCER RESEARCH AND TREATMENT
- Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition
- (2018) Brittany Haynes et al. CANCER TREATMENT REVIEWS
- The comings and goings of PARP-1 in response to DNA damage
- (2018) John M. Pascal DNA REPAIR
- First-in-human phase 1 study of the PARP/tankyrase inhibitor 2X-121 (E7449) as monotherapy in patients with advanced solid tumors and validation of a novel drug response predictor (DRP) mRNA biomarker.
- (2018) Elizabeth Ruth Plummer et al. JOURNAL OF CLINICAL ONCOLOGY
- CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions
- (2018) Michal Zimmermann et al. NATURE
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interplay of Histone Marks with Serine ADP-Ribosylation
- (2018) Edward Bartlett et al. Cell Reports
- Nuclear poly(ADP-ribose) activity is a therapeutic target in amyotrophic lateral sclerosis
- (2018) L. McGurk et al. Acta Neuropathologica Communications
- PARP inhibition induces Akt-mediated cytoprotective effects through the formation of a mitochondria-targeted phospho-ATM-NEMO-Akt-mTOR signalosome
- (2018) Antal Tapodi et al. BIOCHEMICAL PHARMACOLOGY
- Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors
- (2018) Asima Mukhopadhyay et al. BIOCHEMICAL PHARMACOLOGY
- PARPs in genome stability and signal transduction: implications for cancer therapy
- (2018) Luca Palazzo et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Development of PARP and Immune-Checkpoint Inhibitor Combinations
- (2018) Ross A Stewart et al. CANCER RESEARCH
- PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
- (2018) Jianfeng Shen et al. CANCER RESEARCH
- PARP family enzymes: regulation and catalysis of the poly(ADP-ribose) posttranslational modification
- (2018) Marie-France Langelier et al. CURRENT OPINION IN STRUCTURAL BIOLOGY
- PARP-1 (Poly[ADP-Ribose] Polymerase-1)
- (2018) Rhéure Alves-Lopes et al. HYPERTENSION
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structural basis for DNA break recognition by ARTD2/PARP2
- (2018) Ezeogo Obaji et al. NUCLEIC ACIDS RESEARCH
- Poly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson’s disease
- (2018) Tae-In Kam et al. SCIENCE
- PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
- (2018) Liya Ding et al. Cell Reports
- Targeting Wnt-driven cancers: Discovery of novel tankyrase inhibitors
- (2017) Martina Ferri et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells
- (2017) Stephanie A. Yazinski et al. GENES & DEVELOPMENT
- PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes
- (2017) Rebecca Gupte et al. GENES & DEVELOPMENT
- Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2
- (2017) Amit M. Oza et al. GYNECOLOGIC ONCOLOGY
- Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease
- (2017) Karim Gariani et al. JOURNAL OF HEPATOLOGY
- PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis
- (2017) Partha Mukhopadhyay et al. JOURNAL OF HEPATOLOGY
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
- (2017) Elizabeth M Swisher et al. LANCET ONCOLOGY
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
- (2017) Sani H. Kizilbash et al. MOLECULAR CANCER THERAPEUTICS
- Serine ADP-Ribosylation Depends on HPF1
- (2017) Juan José Bonfiglio et al. MOLECULAR CELL
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- Expanding functions of ADP-ribosylation in the maintenance of genome integrity
- (2017) K. Martin-Hernandez et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Metabolic roles of poly(ADP-ribose) polymerases
- (2017) András Vida et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- PARPing for balance in the homeostasis of poly(ADP-ribosyl)ation
- (2017) Harald Schuhwerk et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Poly ADP-ribose polymerase-1: Beyond transcription and towards differentiation
- (2017) Tina Jubin et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Poly(ADP-ribose) polymerase activity and inhibition in cancer
- (2017) Caleb Dulaney et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies
- (2017) Paul Lesueur et al. Oncotarget
- Macrodomains: Structure, Function, Evolution, and Catalytic Activities
- (2016) Johannes Gregor Matthias Rack et al. Annual Review of Biochemistry
- Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
- (2016) Yvette Drew et al. BRITISH JOURNAL OF CANCER
- NAD + Replenishment Improves Lifespan and Healthspan in Ataxia Telangiectasia Models via Mitophagy and DNA Repair
- (2016) Evandro Fei Fang et al. Cell Metabolism
- Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer
- (2016) Suresh S. Ramalingam et al. CLINICAL CANCER RESEARCH
- Poly(ADP-Ribose) Polymerases in Aging - Friend or Foe?
- (2016) András Vida et al. CURRENT PROTEIN & PEPTIDE SCIENCE
- Mitochondrial poly(ADP-ribose) polymerase: The Wizard of Oz at work
- (2016) Attila Brunyanszki et al. FREE RADICAL BIOLOGY AND MEDICINE
- Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy
- (2016) Zachary B Jenner et al. Future Oncology
- PARP inhibition and postinfarction myocardial remodeling
- (2016) Robert Halmosi et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors
- (2016) Ann-Gerd Thorsell et al. JOURNAL OF MEDICINAL CHEMISTRY
- An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy
- (2016) Ying-Qing Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- HPF1/C4orf27 Is a PARP-1-Interacting Protein that Regulates PARP-1 ADP-Ribosylation Activity
- (2016) Ian Gibbs-Seymour et al. MOLECULAR CELL
- Replication fork stability confers chemoresistance in BRCA-deficient cells
- (2016) Arnab Ray Chaudhuri et al. NATURE
- Neuroprotective Effects of Poly(ADP-ribose)polymerase Inhibitor Olaparib in Transient Cerebral Ischemia
- (2016) Fei Teng et al. NEUROCHEMICAL RESEARCH
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- ADP-ribose–derived nuclear ATP synthesis by NUDIX5 is required for chromatin remodeling
- (2016) Roni H. G. Wright et al. SCIENCE
- Cultured networks of excitatory projection neurons and inhibitory interneurons for studying human cortical neurotoxicity
- (2016) Jin-Chong Xu et al. Science Translational Medicine
- Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
- (2016) Y. Pommier et al. Science Translational Medicine
- Olaparib significantly delays photoreceptor loss in a model for hereditary retinal degeneration
- (2016) Ayse Sahaboglu et al. Scientific Reports
- Non-NAD-Like poly(ADP-Ribose) Polymerase-1 Inhibitors effectively Eliminate Cancer in vivo
- (2016) Colin Thomas et al. EBioMedicine
- New Facets in the Regulation of Gene Expression by ADP-Ribosylation and Poly(ADP-ribose) Polymerases
- (2015) Keun Woo Ryu et al. CHEMICAL REVIEWS
- PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice
- (2015) M. A. Ghonim et al. CLINICAL SCIENCE
- The rise and fall of poly(ADP-ribose): An enzymatic perspective
- (2015) John M. Pascal et al. DNA REPAIR
- Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study
- (2015) Minesh P. Mehta et al. JOURNAL OF NEURO-ONCOLOGY
- PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4+ T cell function
- (2015) Mohamed A Ghonim et al. Journal of Translational Medicine
- The Role of Poly(ADP-ribose) Polymerase-1 in Rheumatoid Arthritis
- (2015) Samuel García et al. MEDIATORS OF INFLAMMATION
- Deciphering the Insights of Poly(ADP-Ribosylation) in Tumor Progression
- (2015) María Isabel Rodríguez et al. MEDICINAL RESEARCH REVIEWS
- Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function
- (2015) Felix Y. Feng et al. MOLECULAR CELL
- PARPs and ADP-Ribosylation: 50 Years … and Counting
- (2015) W. Lee Kraus MOLECULAR CELL
- REV7 counteracts DNA double-strand break resection and affects PARP inhibition
- (2015) Guotai Xu et al. NATURE
- E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling
- (2015) Sharon McGonigle et al. Oncotarget
- Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples
- (2014) M J Patterson et al. BRITISH JOURNAL OF CANCER
- Pharmacological Inhibition of Poly(ADP-Ribose) Polymerases Improves Fitness and Mitochondrial Function in Skeletal Muscle
- (2014) Eija Pirinen et al. Cell Metabolism
- Tankyrase Inhibitors as Therapeutic Targets for Cancer
- (2014) Ahmed Kamal et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Protein ADP-ribosylation and the cellular response to DNA strand breaks
- (2014) K.W. Caldecott DNA REPAIR
- Poly(ADP-ribose) polymerases in double-strand break repair: Focus on PARP1, PARP2 and PARP3
- (2014) Carole Beck et al. EXPERIMENTAL CELL RESEARCH
- Nitric Oxide (NO) Releasing Poly ADP-ribose Polymerase 1 (PARP-1) Inhibitors Targeted to Glutathione S-Transferase P1-Overexpressing Cancer Cells
- (2014) Anna E. Maciag et al. JOURNAL OF MEDICINAL CHEMISTRY
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- PARP inhibitor, olaparib ameliorates acute lung and kidney injury upon intratracheal administration of LPS in mice
- (2014) Kunal Kapoor et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Allosteric activation of the RNF146 ubiquitin ligase by a poly(ADP-ribosyl)ation signal
- (2014) Paul A. DaRosa et al. NATURE
- A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a Pediatric Brain Tumor Consortium report†
- (2014) Jack M. Su et al. NEURO-ONCOLOGY
- The role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapy
- (2014) M Li et al. ONCOGENE
- Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699)
- (2014) Selvi Durmus et al. PHARMACEUTICAL RESEARCH
- Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis
- (2014) S. A. Andrabi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PARP Inhibitor with Selectivity Toward ADP-Ribosyltransferase ARTD3/PARP3
- (2013) Anders E. G. Lindgren et al. ACS Chemical Biology
- Parp-2 is required to maintain hematopoiesis following sublethal -irradiation in mice
- (2013) J. Farres et al. BLOOD
- The NAD+/Sirtuin Pathway Modulates Longevity through Activation of Mitochondrial UPR and FOXO Signaling
- (2013) Laurent Mouchiroud et al. CELL
- BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
- (2013) Y. Shen et al. CLINICAL CANCER RESEARCH
- Poly(ADP-ribosylation) and Neoplastic Transformation: Effect of PARP Inhibitors
- (2013) Francesca Donà et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Co-ordination of base excision repair and genome stability
- (2013) Jason L. Parsons et al. DNA REPAIR
- Tankyrases as drug targets
- (2013) Lari Lehtiö et al. FEBS Journal
- The recognition and removal of cellular poly(ADP-ribose) signals
- (2013) Eva Barkauskaite et al. FEBS Journal
- Poly(ADP-ribose) polymerase 2 contributes to neuroinflammation and neurological dysfunction in mouse experimental autoimmune encephalomyelitis
- (2013) Amit Kamboj et al. Journal of Neuroinflammation
- Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond
- (2013) Nicola J. Curtin et al. MOLECULAR ASPECTS OF MEDICINE
- Poly(ADP-ribose): PARadigms and PARadoxes
- (2013) Alexander Bürkle et al. MOLECULAR ASPECTS OF MEDICINE
- Poly(ADP-ribose) signaling in cell death
- (2013) László Virág et al. MOLECULAR ASPECTS OF MEDICINE
- PARP-1 and gene regulation: Progress and puzzles
- (2013) W. Lee Kraus et al. MOLECULAR ASPECTS OF MEDICINE
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
- (2013) J. Murai et al. MOLECULAR CANCER THERAPEUTICS
- Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss
- (2013) Yunjong Lee et al. NATURE NEUROSCIENCE
- Base Excision Repair
- (2013) H. E. Krokan et al. Cold Spring Harbor Perspectives in Biology
- The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells
- (2013) Silvana B. De Lorenzo et al. Frontiers in Oncology
- The Role of PARP-1 and PARP-2 Enzymes in Metabolic Regulation and Disease
- (2012) Péter Bai et al. Cell Metabolism
- Role of poly(ADP-ribose) polymerases in the regulation of inflammatory processes
- (2012) Péter Bai et al. FEBS LETTERS
- Poly(ADP-Ribose) Polymerase 1 Inhibition Improves Coronary Arteriole Function in Type 2 Diabetes Mellitus
- (2012) Soo-Kyoung Choi et al. HYPERTENSION
- Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor
- (2012) Joana C d’Avila et al. Journal of Neuroinflammation
- Reprogramming cellular events by poly(ADP-ribose)-binding proteins
- (2012) Jana Krietsch et al. MOLECULAR ASPECTS OF MEDICINE
- Increased PARP-1 Association with DNA in Alkylation Damaged, PARP-Inhibited Mouse Fibroblasts
- (2012) P. S. Kedar et al. MOLECULAR CANCER RESEARCH
- Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors
- (2012) Elisabet Wahlberg et al. NATURE BIOTECHNOLOGY
- Tankyrase-targeted therapeutics: expanding opportunities in the PARP family
- (2012) Jenna L. Riffell et al. NATURE REVIEWS DRUG DISCOVERY
- New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
- (2012) Bryan A. Gibson et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Structural Basis for DNA Damage-Dependent Poly(ADP-ribosyl)ation by Human PARP-1
- (2012) M.-F. Langelier et al. SCIENCE
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
- (2012) Ashish Juvekar et al. Cancer Discovery
- Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers
- (2011) Tomasz Zaremba et al. BIOCHEMICAL JOURNAL
- Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines
- (2011) A Peasland et al. BRITISH JOURNAL OF CANCER
- PARP-1 Inhibition Increases Mitochondrial Metabolism through SIRT1 Activation
- (2011) Péter Bai et al. Cell Metabolism
- Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
- (2011) Barbara Norquist et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice
- (2011) M. Ali et al. MOLECULAR CANCER THERAPEUTICS
- The macro domain protein family: Structure, functions, and their potential therapeutic implications
- (2011) Weidong Han et al. MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH
- Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
- (2011) Neil Johnson et al. NATURE MEDICINE
- Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
- (2011) A. G. Patel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Iduna is a poly(ADP-ribose) (PAR)-dependent E3 ubiquitin ligase that regulates DNA damage
- (2011) H. C. Kang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PARP inhibitors: New tools to protect from inflammation
- (2010) Vincenzo Giansanti et al. BIOCHEMICAL PHARMACOLOGY
- Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers
- (2010) C. Powell et al. CANCER TREATMENT REVIEWS
- 53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
- (2010) Samuel F. Bunting et al. CELL
- Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
- (2010) A. Mukhopadhyay et al. CLINICAL CANCER RESEARCH
- Gene Expression Profile ofBRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
- (2010) Panagiotis A. Konstantinopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic
- (2010) Dana V. Ferraris JOURNAL OF MEDICINAL CHEMISTRY
- THERAPEUTIC INJECTION OF PARP INHIBITOR INO-1001 PRESERVES CARDIAC FUNCTION IN PORCINE MYOCARDIAL ISCHEMIA AND REPERFUSION WITHOUT REDUCING INFARCT SIZE
- (2010) Jan P. Roesner et al. SHOCK
- Inhibition of matrix metalloproteinase-2 by PARP inhibitors
- (2009) Adrian C. Nicolescu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- A Phase IB Trial of Intravenous INO-1001 Plus Oral Temozolomide in Subjects with Unresectable Stage-III or IV Melanoma
- (2009) Agop Y. Bedikian et al. CANCER INVESTIGATION
- Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2-Mutated Ovarian Carcinoma
- (2009) W. Sakai et al. CANCER RESEARCH
- Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors
- (2009) Philip Jones et al. JOURNAL OF MEDICINAL CHEMISTRY
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of the Peroxynitrite-Poly(ADP-Ribose) Polymerase Pathway in Human Disease
- (2008) Pal Pacher et al. AMERICAN JOURNAL OF PATHOLOGY
- Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
- (2008) R. Plummer et al. CLINICAL CANCER RESEARCH
- Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin
- (2008) B. Evers et al. CLINICAL CANCER RESEARCH
- 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
- (2008) Keith A. Menear et al. JOURNAL OF MEDICINAL CHEMISTRY
- A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial
- (2008) David A. Morrow et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- Tankyrase function at telomeres, spindle poles, and beyond
- (2007) Susan J. Hsiao et al. BIOCHIMIE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started